Abstract
For patients with hematologic malignancies at high risk of relapse who do not have matched donors, a suitable alternative stem cell source is the HLA-haploidentical 2- or 3-loci mismatched family donor who is readily available for nearly all patients. Transplantation across the major HLA barrier is associated with strong T-cell alloreactions, which were originally manifested as a high incidence of severe GVHD and graft rejection. The present overview of the 7th symposium on haplidentical transplantation that took place at the Weizmann Institute on February 2014, shows how these obstacles to successful transplantation can now be overcome. The review also discusses the advantages and drawbacks of current options for full haplotype-mismatched transplantation and highlights innovative approaches for rebuilding immunity, reducing leukemia relapse and improving survival after transplantation. In addition, new modalities for immune tolerance induction following nonmyeloablative conditioning are discussed, showing new options for treatment of elderly patients who cannot tolerate myeloablative conditioning protocols, as well as novel strategies for immune tolerance and chimerism induction as a platform for cell therapy and organ transplantation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning
Experimental Hematology & Oncology Open Access 16 July 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Reisner Y, Itzicovitch L, Meshorer A, Sharon N . Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci USA 1978; 75: 2933–2936.
Reisner Y, Kapoor N, O'Reilly RJ, Good RA . Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 1980; 2: 1320–1324.
Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Dupont B, Good RA et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 2: 327–331.
Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B et al. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983; 61: 341–348.
Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340: 508–516.
Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 2014; 371: 434–446.
Reisner Y, Ben-Bassat I, Douer D, Kaploon A, Schwartz E, Ramot B . Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc Natl Acad Sci USA 1986; 83: 4012–4015.
Kernan NA, Bordignon C, Keever CA, Cunningham I, Castro-Malaspina H, Collins NH et al. Graft failures after T cell depleted marrow transplants for leukemia: clinical and in vitro characteristics. Transplant Proc. 1987; 19: 29–32.
Lapidot T, Terenzi A, Singer TS, Salomon O, Reisner Y . Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989; 73: 2025–2032.
Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y . Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995; 1: 1268–1273.
Bachar-Lustig E, Li HW, Gur H, Krauthgamer R, Marcus H, Reisner Y . Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1(+)Lin(-) bone marrow progenitor cells: synergism with non-alloreactive (host x donor)F(1) T cells. Blood 1999; 94: 3212–3221.
Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948–3955.
Reisner Y, Martelli MF . Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today. 1995; 16: 437–440.
Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.
Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–3454.
Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cells Mol Dis 2008; 40: 9–13.
Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood Cells Mol Dis 2014; 124: 822–826.
Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574–3581.
Bastien JP, Roy J, Roy DC . Selective T-cell depletion for haplotype- mismatched allogeneic stem cell transplantation. Semin Oncol 2012; 39: 674–682.
Perruccio K, Topini F, Tosti A, Carotti A, Burchielli E, Ruggeri L et al. Optimizing a photoallodepletion protocol for adoptive immunotherapy after haploidentical SCT. Bone Marrow Transplant 2012; 47: 1196–1200.
Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 2014; 123: 3895–3905.
Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921–3928.
Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 2014; 124: 638–644.
Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood Cells Mol Dis. 2011; 117: 1061–1070.
Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2013; 121: 5113–5123.
Waldmann H . Drug minimization in transplantation: an opinion. Curr Opin Organ Transplant 2014; 19: 331–333.
Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362–368.
Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S . Induced immune tolerance for kidney transplantation. Engl J Med 2011; 365: 1359–1360.
Kawai T, Sachs DH, Sprangers B, Spitzer TR, Saidman SL, Zorn E et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant 2014; 14: 1599–1611.
Ciurea SO, Champlin RE . Donor selection in T cell—replete haploidentical hematopoietic stem cell transplantation: knowns unknowns, and controversies. Biol Blood Marrow Transplant 2013; 19: 180–184.
Schwartz R, Dameshek W . Drug-induced immunological tolerance. Nature 1959; 183: 1682–1683.
Berenbaum MC, Brown IN . Dose-response relationships for agents inhibiting the immune response. Immunology 1964; 7: 65–71.
Owens AH Jr, Santos GW . The effect of cytotoxic drugs on graft-versus-host disease in mice. Transplantation 1971; 11: 378–382.
Brodsky RA, Luznik L, Bolaños-Meade J, Leffell MS, Jones RJ, Fuchs EJ . Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplantation 2008; 42: 523–527.
Luznik L, Bolños-Meade Javier, Marianna Zahurak B, Chen AR, Smith BD, Brodsky R et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood Cells Mol Dis. 2010; 115: 3224–3230.
Acknowledgements
We thank Dr Esti Bachar-Lustig for her assistance in preparing this manuscript. YR holds the Henry Drake Professorial chair in Transplantation Immunology and is supported in part by a research grant from Roberto and Renata Ruhman.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
YR has received consulting fees, owns equity in and has received grant support from Cell Source Ltd. FA has received consulting fees from Gilead, MSD, Pfizer, Genzyme, and received lecture fees from Gilead, MSD, Pfizer, and Celgene. MFM has declared no competing interests.
Additional information
This article was published as part of a supplement, supported by WIS-CSP Foundation, in collaboration with Gilead, Milteny Biotec, Gamida cell, Adienne Pharma and Biotech, Medac hematology, Kiadis Pharma, Almog Diagnostic.
Rights and permissions
About this article
Cite this article
Reisner, Y., Aversa, F. & Martelli, M. Haploidentical hematopoietic stem cell transplantation: state of art. Bone Marrow Transplant 50 (Suppl 2), S1–S5 (2015). https://doi.org/10.1038/bmt.2015.86
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.86
This article is cited by
-
Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models
Bone Marrow Transplantation (2021)
-
The haematopoietic stem cell transplant survivors’ sense of coherence about their experiences: a qualitative study
Supportive Care in Cancer (2020)
-
A review of infectious complications after haploidentical hematopoietic stem cell transplantations
Infection (2017)
-
Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey
Bone Marrow Transplantation (2016)
-
Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis
Bone Marrow Transplantation (2016)